Last reviewed · How we verify
Etoricoxib + Betamethasone fixed dose
Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation.
Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.
At a glance
| Generic name | Etoricoxib + Betamethasone fixed dose |
|---|---|
| Also known as | Etori + Beta |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | COX-2 inhibitor + corticosteroid combination |
| Target | COX-2 enzyme; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Inflammatory diseases |
| Phase | Phase 3 |
Mechanism of action
Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces prostaglandin synthesis, thereby decreasing inflammation and pain. Betamethasone is a corticosteroid that binds glucocorticoid receptors to suppress immune responses and inflammation. The fixed-dose combination leverages both mechanisms for enhanced anti-inflammatory efficacy in inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Other inflammatory joint disorders
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Hypertension
- Edema
- Corticosteroid-related effects (insomnia, mood changes)
- Increased infection risk
Key clinical trials
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (PHASE1)
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis (PHASE3)
- Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: